Non-inferiority Study to Compare the Efficacy and Safety of Mylan’s Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Investigator:  Mary F Carroll, MD

Status: Recruiting

Phase: 3

Sponsor: Mylan Inc.

Contact: Anne Bergin, 541-706-6597 or

Location: Bend, Oregon (Central Oregon)

Purpose:  To test whether Mylan’s insulin glargine once daily is non-inferior to Lantus® once daily (both administered in combination with other anti-diabetic drugs) based on the change in HbA1c from baseline to 24 weeks.

Inclusion Criteria:

  • Patients with an established diagnosis of T2DM per ADA 2014 criteria who also fulfill the following:
    • Diagnosis established 1 year prior to screening
    • Insulin-naïve OR
    • On Lantus® once daily at stable dose (±15% variation in dose) for at least 3 months prior to screening
  • Body mass index (BMI) of 18.50 to 40.00 kg/m2 at screening (both values inclusive).
  • Stable weight, with no more than 5 kg gain or loss, in the 3 months prior to screening; this information will be collected by patient interview during medical history.
  • Hemoglobin ≥9.0 g/dL at screening
  • Glycosylated hemoglobin (HbA1c) of <10.5% or between 7.5 to 10.5% for insulin naïve patients at screening.

Exclusion Criteria:

  • History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analog preparations used in the trial, OR history of significant allergic drug reactions.
  • History of use of animal insulin within the last 3 years, any insulin other than Lantus® within the last 3 months prior to screening, or use of biosimilar insulin glargine at any time prior to screening.
  • Patients requiring basal-bolus insulin therapy or who in the opinion of the investigator require mealtime insulin in order to achieve glycemic control.
  • Regular use of immune-modulator therapy in the 1 year prior to screening.
  • History of ≥2 episodes of severe hypoglycemia within the 6 months before screening or history of hypoglycemia unawareness (a sample questionnaire is provided in Appendix I) as judged by the investigator.
  • History of ≥1 episode of hyperglycemic hyperosmolar coma or emergency room visits for uncontrolled diabetes leading to hospitalization within the 6 months prior to screening.
  • Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HbSAg) or hepatitis C (HCVAb) antibodies at screening.
  • History of drug or alcohol dependence or abuse during the 1 year prior to screening.
  • Receipt of another investigational drug in the 3 months prior to screening (or as per local regulations), or if the screening visit is within 5 half-lives of another investigational drug (whichever is longer), or scheduled to receive another investigational drug during the current trial period.

See this trial at

For general inquiries, please contact the BMC Research Department at or 877-692-8338.

Back to Clinical Research


Post Comment